PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer

Jeanesse Scerri1, Christian Scerri1, Felix Schäfer-Ruoff2, Simon Fink2, Markus Templin2 and Godfrey Grech3*

1Department of Physiology & Biochemistry, University of Malta, Msida, Malta, 2NMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen, Germany, 3Department of Pathology, University of Malta, Msida, Malta

Protein expression, activation and stability are regulated through interconnected signal transduction pathways resulting in specific cellular states. This study sought to differentiate between the complex mechanisms of intrinsic and acquired trastuzumab resistance, by quantifying changes in expression and activity of proteins (phospho-protein profile) in key signal transduction pathways, in breast cancer cellular models of trastuzumab resistance. To this effect, we utilized a multiplex, bead-based protein assay, DigiWest®, to measure around 100 proteins and protein modifications using specific antibodies. The main advantage of this methodology is the quantification of multiple analytes in one sample, utilising input volumes of a normal western blot. The intrinsically trastuzumab-resistant cell line JIMT-1 showed the largest number of concurrent resistance mechanisms, including PI3K/Akt and RAS/RAF/MEK/ERK activation, β-catenin stabilization by inhibitory phosphorylation of GSK3β, cell cycle progression by Rb suppression, and CREB-mediated cell survival. MAPK (ERK) pathway activation was common to both intrinsic and acquired resistance cellular models. The overexpression of upstream RAS/RAF, however, was confined to JIMT 1; meanwhile, in a cellular model of acquired trastuzumab resistance generated in this study (T15), entry into the ERK pathway seemed to be mostly mediated by PKCα activation. This is a novel observation and merits further investigation that can lead to new therapeutic combinations in HER2-positive breast cancer with acquired therapeutic resistance.

KEYWORDS
acquired resistance, breast cancer, phospho-profile, PKC/MEK/ERK, signalosome, HER2 positive, patient stratification
**Introduction**

**HER2 and trastuzumab**

The human epidermal growth factor receptor 2 (HER2) protein is overexpressed in approximately 15% of breast cancers (1). Having no known ligands, it forms heterodimers with other members of the HER family of receptor tyrosine kinases (HER1/EGFR, HER3, HER4) (2). HER2 activation results in the phosphorylation and activation of multiple downstream signaling proteins, including phospholipase C γ1 (PLCγ1), phosphatidylinositol 3-kinase (PI3K) regulatory and catalytic subunits, RasGAP, and heat shock protein 90 (3). The ensuing signaling cascade, mostly represented by the PI3K/Akt and RAS/RAF/ERK pathways, leads to uncontrolled cellular proliferation and invasion. Protein phosphatase 2A (PP2A), a ubiquitous serine/threonine phosphatase, is also a central regulatory component of PI3K/Akt pathway; its inactivation through phosphorylation at its tyrosine residue p.tyr307 has been found to be increased in HER2-positive tumor samples and correlated to tumor progression (4). Of interest, HER2 signaling increases c-myc phosphorylation at Ser62 and is maintained through attenuation of the phosphatase, PP2A (5). In fact, PP2A activators promote c-myc protein degradation (6). Clinically, high nuclear myc staining is positively associated with lymph-node positive disease in HER2 amplified breast cancer tumors (7). Hence, the HER2-MYC-PP2A axis is of clinical relevance.

The human epidermal growth factor receptor 2 (HER2) receptor (8). The inhibition of heterodimer formation with other HER family members leads to reduced VEGF-mediated angiogenesis (13). Moreover, trastuzumab resistance mechanisms (14). Trastuzumab is always administered adjuvantly to chemotherapeutic agents, where it also inhibits the repair of chemotherapy-induced DNA damage (15).

**Trastuzumab resistance mechanisms**

Nonetheless, intrinsic resistance to the drug in some cases, and tumour recurrence due to acquired resistance in others, are important caveats of the targeted therapy (16). Mechanisms of trastuzumab-HER2 binding inhibition are associated with intrinsic resistance. Steric hindrance by cell surface proteins such as mucin-4 (MUC4) inhibits this binding (17); sensitivity to trastuzumab was enhanced upon knockdown of MUC4 expression in a JIMT-1 cell model (18), suggesting that MUC4 occupies the trastuzumab-binding sites of HER2. Overexpression of stem cell marker CD44 and its ligand, hyaluronan, also mask the trastuzumab binding domain on the HER2 ED and provide an independent prognostic factor for poor disease-free survival in HER2 positive patients treated with adjuvant trastuzumab (19). Proteolytic cleavage of the HER2 receptor generates a constitutively activated, truncated HER2 receptor lacking the ED, p95-HER2, which is associated with lymph node involvement (20) and trastuzumab resistance (21), attributed to the absence of the trastuzumab-binding domain.

Deregulation of signalling pathways downstream to HER2, and the activation of alternative cellular proliferation pathways, are alternative trastuzumab resistance mechanisms. Suppressed PTEN phosphatase activity prevents trastuzumab-induced growth arrest through sustained PI3K/AKT phosphorylation and signal transduction (22). A combination of low PTEN expression and PIK3CA oncogenic mutations predict trastuzumab response in HER2-positive breast cancer patients (23). In addition, trastuzumab-induced growth arrest of HER2-positive tumour cells is counteracted by an increase in insulin-like growth factor-1 receptor (IGF-IR) signalling (24). IGF-IR mediated trastuzumab-resistance is attributed to enhanced degradation of p27 and hence release from cell cycle arrest induced by trastuzumab treatment (25). Resistance to trastuzumab was also associated with increased expression of c-Met (26), and CAV-1 involved in caveolae-mediated endocytosis (27).

Immune escape is another mechanism of trastuzumab resistance. Genomic polymorphisms in FcγRIIIa that significantly suppress the affinity of IgG1 antibodies to the immune cell Fcγ receptor will impair ADCC activation (28). Furthermore, exosomes may transfer transforming growth factor beta 1 (TGFβ1), an immunosuppressive cytokine, and programmed death-ligand-1 (PD-L1), a lymphocyte activation inhibitor, to tumour cells. The presence of these exosomes was correlated with resistance to ADCC, suggesting a role of exosomes in suppressed immune-mediated response to trastuzumab (29). Exosomes generated by SKBR3 cell lines are...
also positive for the receptor, and may act as decoy by binding to trastuzumab, reducing its availability to target tumour cells (30).

### High-throughput biomarker detection

In addition to diagnostic biomarkers, the discovery of predictive markers of treatment resistance is a key aspect of personalized medicine. In the era of network medicine and high-throughput "omics", it is important to study the interplay of the different complex mechanisms leading to drug resistance. The classification of breast cancer into molecular subtypes with prognostic and predictive implications, based on high-throughput gene expression data, has led to the development of gene panels such as the Oncotype DX (31) or the MammaPrint™ (32) assays. For Her2-positive breast cancer, however, there is no FDA-approved gene panel to date for the clinical prediction of response to trastuzumab-containing treatment regimes. The use of bead-based, multiplex RNA (33) and protein (34) assays has shown effectiveness in medium- to high-throughput cancer biomarker discovery and detection.

This study sought to differentiate between the complex mechanisms of intrinsic and acquired trastuzumab resistance, by quantifying changes in expression and activity of proteins in key signal transduction pathways, in cellular models of resistance. We utilized JIMT-1 as a cellular model of intrinsic resistance, and generated an acquired trastuzumab resistance model (T15) to study differential signaling signatures.

### Materials and methods

#### Generation of trastuzumab-resistant cell line

SKBR3 cells with acquired trastuzumab resistance were obtained by conditioning with the drug as described by Zazo et al. (35). Briefly, the cell line (ATCC® HTB-30™), grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% foetal bovine serum (FBS) and 1% GlutaMAX™ (Thermo Fisher Scientific, Waltham, MA), was acclimatized for 30 days in 10µg/mL trastuzumab followed by long-term culturing in medium containing 15µg/mL of the drug. Resistance to trastuzumab was confirmed by cell viability assay (MTT), which showed a maintenance of ≥80% viability after 72 hours incubation with 25-100µg/mL trastuzumab concentration (compared to the parent cells which showed reduced viability at these drug concentrations). The resulting cell line will be henceforth referred to as T15. The JIMT-1 cell line (DSMZ ACC-589), kindly donated by M. Barok at the University of Helsinki, Finland, was cultured with 10% heat-inactivated FBS.

#### Bead-based, multiplex phosphoprotein profiling

High-throughput multiplex phosphoprotein profiling was subsequently carried out by the DigiWest® technique, as described by Treindl et al. (36), on the parental and conditioned cell lines. Briefly, cell pellets containing 5x10⁵ cells or more were lysed, and gel electrophoresis and blotting onto PVDF membranes was performed using the NuPAGE system as recommended by the manufacturer (Life Technologies, Carlsbad, CA, USA). The membranes were washed in PBST, then incubated in NHS-PEG12-Biotin (50µM) in PBST for 1 hour to biotinylate the blotted proteins, followed by another wash in PBST and drying. Individual sample lanes were cut into 96 molecular weight fractions (0.5mm each), with the separated proteins in each fraction eluted in 96-well plates using 10µL elution buffer (8M urea, 1% Triton-X100 in 100mM Tris-HCl pH 9.5) per well. The eluted proteins from each molecular weight fraction were then coupled with neutravidin-coated Luminex beads (MagPlex, Luminex, Austin, TX, USA) of a specific bead identity (red-infrared spectral wavelength), yielding 96 size-specific bead identities per sample. 384 Luminex bead sets were employed and the protein-loaded beads from 4 different sample lanes were pooled into a bead-mix having a concentration of 40 beads/µL in carboxy block storage buffer (CBS), which was sufficient for over 100 antibody incubations. Antibodies specific proteins and phosphoproteins with roles in HER2 downstream signaling pathways and other aforementioned mechanisms of interest were utilized (Table 1).

For each target protein or phosphoprotein to be quantified, an aliquot of the DigiWest bead-mixes was added to a well of a 96-well plate containing 50µL assay buffer (Blocking Reagent for ELISA supplemented with 0.2% milk powder, 0.05% Tween-20, and 0.02% sodium azide, Roche). Following a brief incubation in assay buffer, the buffer was discarded by keeping the 96-well plate on a magnet. The beads were then incubated with 30µL of a specific primary antibody diluted in assay buffer per well. After overnight incubation at 15°C on a shaker, the bead-mixes were washed twice with PBST and PE-labelled (Phycoerythrin) secondary antibodies (Dianova) specific to the primary antibody species were added and incubated for 1 hour at 23°C. Beads were washed twice and resuspended in PBST prior to the readout on a Luminex® FlexMAP 3D®

For the quantification of the antibody specific signals, the DigiWest® analysis tool (version 3.8.6.1, Excel-based) was employed. This tool uses the 96 values for each initial lane obtained from the Luminex® measurements on the 96 molecular weight fractions, identifies the peaks at the appropriate molecular weight, calculates a baseline using the local background, and integrates the peaks. The obtained values are based on relative fluorescence (AIF, accumulated fluorescence intensity). For analysis, the data was normalized to the total.
| Pathway       | Analyte                          | Supplier          | Cat. No. | Species + Clonality | JIMT & SKBR3 | T15 | JIMT & T15 |
|--------------|----------------------------------|-------------------|----------|---------------------|--------------|-----|------------|
| PI3K/mTOR    | 4E-BP1                           | Epitomics         | 1557-1   | Rb mAb              | 2490         | 240 | 283        | 3.37 | 0.24 |
| PI3K/mTOR    | 4E-BP1 - phosphoThr70            | Cell Signaling    | 9455     | Rb pAb              | 754          | 119 | 164        | 2.66 | 0.46 |
| PI3K         | Akt                              | Cell Signaling    | 4685     | Rb mAb              | 3567         | 2125| 2901       | 0.75 | 0.45 |
| PI3K         | Akt - phosphoSer129              | Cell Signaling    | 13461    | Rb mAb              | 1            | 1   | 328        | 0.00 | 8.36 |
| mTOR         | AMPK alpha - phosphoThr172       | Cell Signaling    | 2532     | Rb pAb              | 657          | 418 | 544        | 0.65 | 0.38 |
| MEK/ERK      | A-Raf - phosphoSer33/37/Thr41, active | Cell Signaling | 8814     | Rb mAb              | 3541         | 1   | 1179       | 0.00 | 0.79 |
| MEK/ERK      | b-Raf - phosphoSer445            | Cell Signaling    | 2696     | Rb pAb              | 208          | 143 | 160        | 0.54 | 0.16 |
| Cell cycle   | CDK4                             | Cell Signaling    | 12790    | Rb mAb              | 32451        | 3328| 2931       | 3.29 | -0.18 |
| PI3K         | c-myc_57kDa                      | Cell Signaling    | 9402     | Rb pAb              | 207          | 205 | 241        | 0.01 | 0.23 |
| PI3K         | c-myc_70kDa                      | Cell Signaling    | 9402     | Rb pAb              | 549          | 520 | 337        | 0.08 | -0.63 |
| PI3K         | c-myc_Total                      | Cell Signaling    | 9402     | Rb pAb              | 756          | 724 | 577        | 0.06 | -0.33 |
| MEK/ERK      | c-Raf                            | Cell Signaling    | 9422     | Rb pAb              | 632          | 161 | 135        | 1.97 | -0.25 |
| MEK/ERK      | c-Raf - phosphoSer259            | Cell Signaling    | 9421     | Rb pAb              | 2423         | 873 | 874        | 1.47 | 0.00 |
| MEK/ERK      | c-Raf - phosphoSer289/296/301    | Cell Signaling    | 9431     | Rb pAb              | 374          | 186 | 168        | 1.01 | -0.15 |
| PI3K         | CREB - phosphoSer133             | Cell Signaling    | 9198     | Rb pAb              | 177          | 1   | 56         | 7.47 | 5.80 |
| PI3K         | eIF4E                            | Cell Signaling    | 2067     | Rb pAb              | 13776        | 16186| 17424      | -0.23 | 0.11 |
| PI3K         | eIF4E - phosphoSer209            | Cell Signaling    | 9741     | Rb pAb              | 348          | 927 | 1193       | -1.41 | 0.36 |
| MEK/ERK      | Elk-1                            | Cell Signaling    | 9182     | Rb pAb              | 653          | 656 | 813        | -0.01 | 0.31 |
| MEK/ERK      | Elk-1 - phosphoSer383            | Cell Signaling    | 9186     | ms mAb              | 644          | 1580| 1651       | -1.29 | 0.06 |
| MEK/ERK      | Erk1/2 (MAPK p44/42), p42        | Cell Signaling    | 4695     | Rb mAb              | 17917        | 30972| 41263       | -0.79 | 0.41 |
| MEK/ERK      | Erk1/2 (MAPK p44/42), p44        | Cell Signaling    | 4695     | Rb mAb              | 3100         | 1702| 1774       | 0.87 | 0.06 |
| MEK/ERK      | Erk1/2 (MAPK p44/42), Total      | Cell Signaling    | 4695     | Rb mAb              | 21016        | 32673| 45036       | -0.64 | 0.40 |
| MEK/ERK      | Erk1/2 (MAPK p44/42) - phosphoThr202/Thr204, p42 | Cell Signaling | 4370     | Rb mAb              | 4211         | 788 | 1190       | 2.42 | 2.60 |
| MEK/ERK      | Erk1/2 (MAPK p44/42) - phosphoThr202/Thr204, p42 | Cell Signaling | 4370     | Rb mAb              | 1656         | 93  | 294        | 4.16 | 1.67 |
| MEK/ERK      | Erk1/2 (MAPK p44/42) - phosphoThr202/Thr204, Total | Cell Signaling | 4370     | Rb mAb              | 5866         | 880 | 1482       | 2.74 | 0.75 |
| MEK/ERK      | ERK1/2 (MAPK) - phosphoThr202/Tyr204, p42 | Cell Signaling | 9101     | Rb pAb              | 4653         | 257 | 480        | 4.18 | 0.90 |
| MEK/ERK      | ERK1/2 (MAPK) - phosphoThr202/Tyr204, p44 | Cell Signaling | 9102     | Rb pAb              | 1340         | 113 | 143        | 3.57 | 0.34 |
| MEK/ERK      | ERK1/2 (MAPK) - phosphoThr202/Tyr204, Total | Cell Signaling | 9103     | Rb pAb              | 5993         | 368 | 621        | 4.02 | 0.75 |
| MEK/ERK      | Erk2 (MAPK p42)                  | Cell Signaling    | 9108     | Rb pAb              | 2649         | 6720| 10792      | -1.34 | 0.68 |
| WNT          | GSK-3 alpha                      | Cell Signaling    | 4337     | Rb mAb              | 4395         | 4403| 4928       | 0.00 | 0.16 |
| WNT          | GSK3 alpha - phosphoSer21, 51kDa | Cell Signaling    | 9331     | Rb pAb              | 229          | 443 | 409        | -0.95 | -0.11 |
| PI3K/WNT     | GSK3 alpha-beta - phosphoSer21/Ser9, Total | Cell Signaling | 9331     | Rb pAb              | 548          | 443 | 409        | 0.31 | -0.11 |

(Continued)
### TABLE 1 Continued

| Pathway | Analyte | Supplier | Cat. No. | Species + Clonality | Fluorescence Intensity | LOG2 FC rel. to SKBR3 |
|----------|---------|----------|----------|---------------------|------------------------|------------------------|
| PI3K    | GSK3 beta - phosphoTyr216_47kDa | Abcam | ab68476 | Rb mAb | JIMT1: 129, SKBR3: 281 | T15: -0.85, SKBR3: 0.28 |
| PI3K    | GSK3 alpha - phosphoTyr279_51kDa | Abcam | ab68476 | Rb mAb | JIMT1: 706, SKBR3: 148 | T15: 2.50, SKBR3: 0.25 |
| PI3K    | GSK3 alpha/beta - phosphoTyr279/Tyr216_Total | Abcam | ab68476 | Rb mAb | JIMT1: 834, SKBR3: 429 | T15: 1.23, SKBR3: 0.27 |
| PI3K    | GSK3 beta - phosphoSer9 | Cell Signaling | 9336 | Rb pAb | JIMT1: 511, SKBR3: 1 | T15: 9.00, SKBR3: 0.00 |
| HER2    | GSK3 beta | Cell Signaling | 9315 | Rb mAb | JIMT1: 11035, SKBR3: 3642 | T15: 1.60, SKBR3: -0.83 |
| Multiple | HSP 90 | Abcam | ab59459 | Ms mAb | JIMT1: 3595, SKBR3: 5008 | T15: -0.48, SKBR3: 0.82 |
| IGF1    | IGF1 receptor beta (Inulin receptor beta, CD221) | Cell Signaling | 3018 | Rb mAb | JIMT1: 308, SKBR3: 153 | T15: 1.02, SKBR3: 0.12 |
| MEK/ERK MAPKAPK-2 | Cell Signaling | 12155 | Rb mAb | JIMT1: 392, SKBR3: 556 | T15: -0.50, SKBR3: -0.29 |
| MEK/ERK MEK 1 | Cell Signaling | 9124 | Rb pAb | JIMT1: 1128, SKBR3: 610 | T15: 0.89, SKBR3: 0.08 |
| MEK/ERK MEK1 - phosphoThr298 | Cell Signaling | 98195 | Rb mAb | JIMT1: 896, SKBR3: 1 | T15: 9.81, SKBR3: 0.00 |
| MEK/ERK MEK2 | Cell Signaling | 9125 | Rb pAb | JIMT1: 953, SKBR3: 171 | T15: 2.48, SKBR3: -0.38 |
| MEK/ERK Mnk1 | Cell Signaling | 2195 | Rb mAb | JIMT1: 239, SKBR3: 161 | T15: 0.57, SKBR3: 0.03 |
| MEK/ERK MSK1 - phosphoSer376 | Millipore | 04-384 | Rb mAb | JIMT1: 2302, SKBR3: 2436 | T15: -0.08, SKBR3: 1.93 |
| PI3K/ | mTOR (FRAP) | Cell Signaling | 2983 | Rb mAb | JIMT1: 3077, SKBR3: 1394 | T15: 1.14, SKBR3: 0.68 |
| PI3K/ | mTOR - phosphoSer2448 | Cell Signaling | 5536 | Rb mAb | JIMT1: 1211, SKBR3: 521 | T15: 1.22, SKBR3: 0.94 |
| MEK/ERK | p38 MAPK | Cell Signaling | 9212 | Rb pAb | JIMT1: 572, SKBR3: 258 | T15: 1.15, SKBR3: 0.08 |
| Cell cycle | p53 | R&D | af1355 | Gt pAb | JIMT1: 9935, SKBR3: 1601 | T15: 2.63, SKBR3: 0.40 |
| PI3K/ | mTOR - p70 S6 kinase | Cell Signaling | 2708 | Rb mAb | JIMT1: 5905, SKBR3: 2365 | T15: 1.32, SKBR3: 0.34 |
| PI3K/ | mTOR - p70 S6 kinase - phosphoThr421/Ser424 | Cell Signaling | 9204 | Rb pAb | JIMT1: 632, SKBR3: 93 | T15: 2.76, SKBR3: 0.92 |
| PI3K    | PDK1 | Cell Signaling | 3062 | Rb pAb | JIMT1: 1398, SKBR3: 808 | T15: 0.79, SKBR3: 0.68 |
| PI3K    | PDK1 - phosphoSer241 | Cell Signaling | 3061 | Rb pAb | JIMT1: 142, SKBR3: 73 | T15: 0.96, SKBR3: 1.39 |
| PI3K    | PI3-kinase p110 delta_110kDa | Santa cruz | sc-7176 | Rb pAb | JIMT1: 734, SKBR3: 220 | T15: 1.74, SKBR3: 0.11 |
| PI3K    | PI3-kinase delta_60kDa | Santa cruz | sc-7176 | Rb pAb | JIMT1: 11463, SKBR3: 12042 | T15: -0.07, SKBR3: -0.08 |
| PI3K    | PI3-kinase delta_Total | Santa cruz | sc-7176 | Rb pAb | JIMT1: 12196, SKBR3: 12262 | T15: -0.01, SKBR3: -0.08 |
| PI3K    | PI3-kinase p110 alpha | Cell Signaling | 4255 | Rb pAb | JIMT1: 31, SKBR3: 253 | T15: -3.05, SKBR3: 0.07 |
| PI3K    | PI3-kinase p110 beta_110kDa | Millipore | 04-400 | Rb mAb | JIMT1: 2897, SKBR3: 916 | T15: 1.66, SKBR3: 0.12 |
| PI3K    | PI3-kinase p110 beta_60kDa | Millipore | 04-400 | Rb mAb | JIMT1: 1514, SKBR3: 1835 | T15: -0.28, SKBR3: -0.14 |
| PI3K    | PI3-kinase p110 beta_Total | Millipore | 04-400 | Rb mAb | JIMT1: 4409, SKBR3: 2750 | T15: -0.68, SKBR3: 0.05 |
| PI3K    | PI3-kinase p85 alpha | Epitomics | 1675-1 | Rb mAb | JIMT1: 363, SKBR3: 87 | T15: 2.06, SKBR3: 0.44 |
| PI3K    | PI3-kinase p85 | Cell Signaling | 4292 | Rb pAb | JIMT1: 437, SKBR3: 129 | T15: 1.76, SKBR3: 0.28 |
| PI3K    | PI3-kinase p85/p55 - phosphoTyr458/Tyr199_55kDa only | Cell Signaling | 4228 | Rb pAb | JIMT1: 336, SKBR3: 3158 | T15: -3.23, SKBR3: 0.00 |
| PI3K    | PKC (pan) - phosphoSer660 | Cell Signaling | 9371 | Rb pAb | JIMT1: 1073, SKBR3: 1180 | T15: -0.14, SKBR3: 1.98 |
| PI3K    | PKC (pan) gamma - phosphoThr514_80kDa | Cell Signaling | 38938 | Rb mAb | JIMT1: 1102, SKBR3: 1141 | T15: 0.05, SKBR3: 1.15 |
| PI3K    | PKC (pan) gamma - phosphoThr514_83kDa | Cell Signaling | 38938 | Rb mAb | JIMT1: 2613, SKBR3: 3150 | T15: -0.27, SKBR3: 0.90 |
| PI3K    | PKC (pan) gamma - phosphoThr514_Total | Cell Signaling | 38938 | Rb mAb | JIMT1: 3715, SKBR3: 4290 | T15: -0.21, SKBR3: 0.97 |
| PI3K    | PKC alpha - phosphoSer657 | Abcam | AB180848 | Rb mAb | JIMT1: 1769, SKBR3: 1122 | T15: 0.66, SKBR3: 1.91 |
| PI3K    | PKC alpha - phosphoThr497 | Abcam | AB76016 | Rb mAb | JIMT1: 1526, SKBR3: 1948 | T15: -0.35, SKBR3: 0.54 |

(Continued)
protein amount corresponding to the sample, and the relative quantification of each protein and phosphoprotein was expressed as log₂ fold-change (FC) in T15 and JIMT-1 as compared to SKBR3. Differentially expressed targets were organized into established signal transduction pathways and phosphosite log₂ FC were used to predict whether each protein was under- or over-activated.

Results and discussion

MEK/ERK pathway is a central mechanism of acquired trastuzumab resistance

Phosphoinositide-dependent kinase-1 (PDK1) activity was significantly increased (log₂ FC(PDK1) = +0.7) in T15. A lack of significant change in RAF expression was expected to be consistent with a lack of alteration in downstream MEK1/2 signaling; however, the MEK/ERK pathway was still found to be overall activated. The expression of total MEK1 was equivalent, while that of MEK2 was slightly downregulated (log₂ FC = -0.36) in T15 when compared to SKBR3. Meanwhile, activated pMEK1 ser217/221/pMEK2ser222/226 (antibody does not distinguish between the two isoforms) was significantly upregulated in T15 (log₂ FC = +1.6). ERK (MAPK) activity reflected the changes observed in its upstream activator, MEK: despite minimal changes in total protein expression (log₂ FC(ERK1) = +0.06, log₂ FC(ERK2) = +0.41), phosphorylated (active) forms of ERK1 and ERK2 were over-represented, thus resulting in a higher ratio of phosphorylated to total ERK1/2 (log₂ FC(pERK1 thr202/tyr204 = +1.7; log₂ FC(pERK2 thr185/tyr187 = +0.6). The results were confirmed with two different antibody clones (Cell

| Pathway          | Analyte                          | Supplier    | Cat. No. | Species + Clonality | JIMT1 SKBR3 | T15 | JIMT1 T15 |
|------------------|----------------------------------|-------------|----------|---------------------|-------------|-----|-----------|
| PI3K             | PKC alpha                        | BD Biosciences | 610107   | Ms mAb              | 1           | 77  | 80        | -6.27 | 0.05      |
| PI3K             | PKC alpha/beta II - phosphoThr638/Thr641 | Cell Signaling | 9375     | Rb pAb              | 980         | 1570| 1473      | -0.68 | -0.09     |
| PI3K             | PIP2A C                          | Cell Signaling | 2259     | Rb mAb              | 5653        | 3171| 2571      | 0.83  | -0.30     |
| PI3K             | PIP2A C - phosphoTyr307          | R&D          | AF3989   | Rb pAb              | 4986        | 20990| 10084     | -2.07 | -1.06     |
| PI3K             | PTEN                             | Cell Signaling | 9552     | Rb pAb              | 228         | 203 | 304       | 0.16  | 0.58      |
| MEK/ERK          | Ras                              | Cell Signaling | 8955     | Rb mAb              | 2280        | 742 | 1103      | 1.62  | 0.57      |
| Cell cycle       | Rb - phosphoSer795               | Cell Signaling | 9301     | Rb pAb              | 149         | 53  | 1         | 1.49  | -5.73     |
| Cell cycle       | Rb - phosphoSer807/Ser811        | Epitomics    | 2004-1   | Rb mAb              | 1618        | 342 | 347       | 2.24  | 0.02      |
| Multiple         | RSK 1 (p90RSK) - phosphoSer380   | Cell Signaling | 9344     | Rb pAb              | 1038        | 306 | 334       | 1.76  | 0.13      |
| Multiple         | RSK 1 (p90RSK) - phosphoThr573   | Abcam        | ab62324  | Rb mAb              | 556         | 115 | 303       | 2.27  | 1.40      |
| Multiple         | RSK 1/2/3                        | Cell Signaling | 9347     | Rb pAb              | 1059        | 438 | 453       | 1.27  | 0.05      |
| Multiple         | RSK 3                            | Epitomics    | 2012-1   | Rb mAb              | 1005        | 409 | 648       | 1.30  | 0.67      |
| Multiple         | RSK 3 - phosphoThr356/Ser360     | Cell Signaling | 9348     | Rb pAb              | 87          | 1   | 104       | 6.45  | 6.70      |
| PI3K/ mTOR       | S6 ribosomal protein             | Cell Signaling | 2317     | Ms mAb              | 6810        | 14092| 11270     | -1.05 | -0.32     |
| PI3K/ mTOR       | S6 ribosomal protein - phosphoSer235/Ser236 | Cell Signaling | 2211     | Rb pAb              | 11823       | 31835| 20663     | -1.43 | -0.62     |
| PI3K/ mTOR       | S6 ribosomal protein - phosphoSer240/Ser244 | Cell Signaling | 2215     | Rb pAb              | 9573        | 38584| 21969     | -2.01 | -0.81     |
| PI3K/ mTOR       | TSC2 (Tuberin)                   | Cell Signaling | 4308     | Rb mAb              | 2138        | 489 | 1073      | 2.13  | 1.13      |
| PI3K/ mTOR       | Tuberin/TSC2 - phosphoSer1387    | Cell Signaling | 23402    | Rb mAb              | 1369        | 233 | 564       | 2.55  | 1.27      |

Antibodies were organized into the main canonical pathways of signal transduction and cellular proliferation. Antibody species: Rb: rabbit, Ms: mouse, Gt: goat; antibody clonality: mAb: monoclonal, pAb: polyclonal. Fluorescence intensity values less than 100 are deemed inaccurate and should be interpreted with caution. Fold changes ≥1 are denoted in light orange and fold changes ≤-1 are denoted in light green.
Signaling product ID 4370 and 9101; log₂ fold changes reported here obtained with the former), both of which bind to ERK1 and ERK2 and give two specific peaks of 44 and 42 kDa, respectively (Figure 1; Table 1). T15 also showed hyper-activation of the ribosomal protein S6 kinase α-5 protein, MSK1 (log₂ FC (pMSK1 ser376) = +1.9; Figure 1). MSK1 is directly phosphorylated by MAPKs at serine 360, threonine 581, and threonine 700, and subsequently autophosphorylates at serine 376 for protein activation (37). Seemingly conflicting roles for MSK1 in breast cancer have been described: it shows tumor suppressor functions by acting as a transcriptional coactivator of P53 and mediating phosphorylation of histone H3 in the transcriptional activation of p21 (37), but has also been associated with epithelial-mesenchymal transition (EMT) and subsequent skeletal metastasis by histone H3 acetylation and phosphorylation of Snail, which downregulates E-cadherin to promote cellular migration and invasion (38).

**Activation of the MEK/ERK pathway is through PKCα activation in acquired resistance**

In the absence of RAF overexpression, entry into the MEK/ERK pathway can be mediated by the protein kinase C (PKC) family, via PDK1. PKCα and PKCγ are both members of the diacylglycerol (DAG) sensitive, Ca²⁺ responsive conventional PKC (cPKC) isoform subgroup. Activation downstream to receptor tyrosine kinases, such as ErbB receptors, involves the Ca²⁺ sensitive recruitment of phosphatidylinositol (4, 5-bisphosphate [PtdIns (4, 5)P2]-specific phospholipases Cγ1/2 (PtdIns-PLCγ1/2) through their SH2 domains; PDK1-dependent activation loop phosphorylation, together with C-terminal phosphorylations events, catalyze PKC activity by maintaining the active conformation of the kinase domains (39). While PKCγ is more specific to the brain, PKCα is
detected in all normal and most tumor tissue types (40). The presence of activated pan-PKC and specifically PKCα was determined by the over-representation of phospho-proteins in T15 (log₂ FC(PKCA) = +0.05; log₂ FC(pPKCA\text{thr245}) = +0.54; log₂ FC(pPKCA\text{ser657}) = +1.91), as well as the overexpression of PDK1-p-ser241, an autophosphorylation site essential for PDK1 activity (Figure 1). Increased levels of this phosphoprotein are a frequent event in breast cancer metastasis, and have been proposed as a candidate for chemosensitisation in innate and acquired resistance (41).

PKC-α, like other protein kinases, plays a role in the regulation of various cellular functions, ranging from cell proliferation and differentiation to control of apoptosis. Requiring HSP90 (log₂ FC in T15 = 0.92) and mTORC2 complex to prime phosphorylation, it is sequentially phosphorylated at Thr497 in the kinase domain by PDK1 and at Thr638 and Ser657 autophosphorylation sites. While in the cytoplasm, the phosphorylated PKC-α is still inactive, until it is recruited to the plasma membrane, where it exerts its functions (42). Its importance in cellular proliferation renders its abnormal expression a transformative event: initial recognition of the role of PKC-α in tumorigenesis was reported by Ways and colleagues (43), where ectopic expression of the isoform in MCF7 cells led to a more aggressive phenotype characterized by increased cell proliferation, anchorage-independent growth, loss of epithelial morphology, and enhanced tumorigenicity in nude mice. Using the same cell line, Gupta et al. (44) attributed the increase in cellular proliferation to ERK activation by PKC-α.

PKC family members were also identified as kinases involved in HER2 endocytosis by Bailey and colleagues (45), by using tansypimycin to inactivate HSP90 (and thus promote receptor internalization for degradation), followed by a kinase inhibitor screen to identify kinases whose inhibition correlated with reduced cell surface clearance of HER2. The activation of PKC by phorbol myristate acetate (PMA), and the specific ectopic expression of constitutively active PKC-α, promoted its co-localization with HER2 into a juxtanuclear compartment without subsequent degradation. Conversely, knockdown of PKC-α by siRNA impaired HER2 trafficking to the ERC. In a previous study, PKC-α was implicated in the positive regulation of cell surface HER2 receptor levels, as assessed by flow cytometry, in breast cancer cell lines classified as HER2+ on immunohistochemistry without gene amplification as determined by fluorescence in situ hybridization (FISH) (46).

Multiple PKC-independent pathways are activated in intrinsic resistance model, JIMT-1

Upon phosphoprotein profiling of JIMT-1 as a HER2-positive breast cancer cell line with intrinsic trastuzumab resistance, it was immediately evident that multiple cell survival and proliferation pathways were simultaneously upregulated in comparison with SKBR3, but these did not involve PKC proteins (Figure 2). Specifically, the RAS/RAF/MEK/ERK pathway was highly activated, together with the overexpression of the highly important kinases, PI3K class Iα (p110β isoform; log₂ FC = +1.7) and PDK1 (log₂ FC = +0.8). Upregulated cell cycle progression was indicated by the highly over-expressed CDK4 (log₂ FC: +3.3) and the overall downregulation of the retinoblastoma-associated protein (Rb) tumor suppressor (log₂ FC(Rb) = +1.6; log₂ FC(pRb\text{ser795/804}) = +2.2; normalized AFI(pRb\text{ser795/804}) = 189 (not detected in SKBR3)). GSK3β activity was suppressed (log₂ FC(GSK3β) = +1.6; AFI (pGSK3β\text{ser9}) = 511 (not detected in SKBR3)), leading to increased expression (log₂ FC: +7.0) and activity (non-phospho-ser33/37/thr41: AFI = 3541; not detected in SKBR3) of β-catenin, which is associated with an increase in transcriptional activation. Enhanced cell survival was indicated by the overall activation of the cAMP-response-element-binding protein (CREB); despite total protein expression being below the cutoff in all cell lines, the active phosphosite at ser133 was not expressed in SKBR3 but expressed (normalized AFI = 177) in JIMT-1 (Figure 2; Table 1).

Control of these complex signal transduction cascades by feedback loop mechanisms makes the interpretation of some phospho-proteomic results more challenging. Specifically, both activators of the S6 ribosomal protein (RPS6), the p70S6 kinase (p70S6K/S6K1) and the ribosomal S6 kinase (p90RSK/RSK1), were activated in both models of resistance (i.e. T15 and JIMT-1), while RPS6 itself was downregulated in both cell lines. Activation of p70S6K was confirmed by the over-representation of its phosphorylation target on mTOR at serine 2448 (47), while activation of RSK1 was confirmed by the over-representation of different activating phosphosites, in both models (Figures 1, 2; Table 1). Also of interest, deregulation of PP2A and the HER2-MYC-PP2A axis were not apparently involved in the intrinsic resistance of JIMT-1 to trastuzumab or the resistance acquired by T15. The PP2A C regulatory subunit was overexpressed at a log₂ FC of 0.83 in JIMT-1 and was not significantly differentially expressed in T15, while its inactivating phosphosite p.tyr307 was significantly underexpressed in both cell lines. Meanwhile, no change in expression of c-myc was observed in the two cell lines in relation to SKBR3 (Table 1).

Clinical perspectives

In this study, we focused on the differential protein expression and phosphorylation events in a cellular model of intrinsic resistance (JIMT-1) and one with generated trastuzumab-induced acquired resistance (T15). PKC-mediated MEK/ERK pathway activation was observed in the acquired model (T15) only. Apart from its above-mentioned functions, PKC-α expression maintains the invasiveness of triple-negative breast cancer.
breast cancer (TNBC) and endocrine resistant cell lines through upregulation of FOXC2, a transcriptional repressor of p120-catenin (CTNND1); a high FOXC2:CTNND1 ratio was also associated with shorter disease free survival in TNBC patients in The Cancer Genome Atlas (TCGA) dataset (48). FOXC2 is an epithelial-mesenchymal transition (EMT) marker, a process known to be significantly associated with HER2-positive, metastatic breast cancer in the clinical setting (49). Cells undergoing EMT commonly show upregulation of metalloproteinases (50, 51), which promote HER2 cleavage/shedding and thus a high ratio of p95:p185 HER2, associated with trastuzumab resistance and poor disease-free survival in HER2+ breast cancer (52). Assessment of the p95:p185 HER2 ratio in plasma exosomes derived from HER2-positive breast cancer patients (30) is a potential tool for the detection of early metastatic disease and monitoring of response to trastuzumab therapy.

Using the DigiWest® methodology, we interrogated major signal transduction pathways to understand the complex interplay of these pathways and changes following resistance to therapy. Bead-based, multiplex (phospho)protein assays are a very efficient means of studying these pathways, whereby the supporting data from many members of the same pathway, rather than a few candidates (as is permitted by traditional Western blotting techniques) lends robustness to the overall observations. The use of this methodology to characterise exosomes for HER2 receptor ratios, FOXC2 and other EMT markers, metalloproteases, TGFβ, and PD-L1, and other markers of therapeutic resistance can accompany the other developments in liquid biopsy, such as circulating tumour cells.

FIGURE 2
Pathways involved in JIMT-1 trastuzumab resistance (log2 FC normalized to SKBR3 signals). AFISimilarly expressed protein: light grey; antibody not available/poor performance: no fill; overexpressed total protein ≥ 1.5-fold (log2 FC ≥ 0.58): light orange; ≥ 2-fold: *; under-expressed total protein ≤ 0.67 (log2 FC ≤ -0.58): light green; ≤ 0.5-fold: *; overexpressed phosphosite ≥ 1.5-fold: orange; ≥ 2-fold: *; underexpressed phosphosite ≤ 0.67: green; ≤ 0.5-fold: *; predicted active protein: dark red outline; predicted inactive protein: dark blue outline.
(CTCs) (53) and patterns of cell-free nucleic acids in plasma (54), as well as protein biomarkers in other biofluids such as tears (55), to predict disease development and progression. The potential use of DigiWest® to quantitate proteins from various sources provides a multiplex method that can be translated to the clinic, since ultra-high throughput proteomics by mass spectroscopy remain challenging to use in the clinical setting. Understanding treatment resistance mechanisms and incorporating multiplex assays in personalised medicine allows the prediction of early therapeutic resistance and prevents the use of non-beneficial therapies.

Conclusion

MAPK (ERK) pathway activation was common to both intrinsic and acquired resistance cellular models. PKC-mediated MEK/ERK pathway activation in the cellular model of acquired trastuzumab resistance generated in this study (T15) was not observed in the intrinsic model, JIMT-1, which is in turn characterized by the PKC-independent activation of various pathways, including PI3K/Akt and RAS/RAF/MEK/ERK activation, β catenin stabilization by inhibitory phosphorylation of GSK3β, cell cycle progression by Rb suppression, and CREB-mediated cell survival. This is a novel observation which merits further investigation that can lead to new therapeutic combinations in HER2-positive breast cancer with acquired therapeutic resistance to trastuzumab.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

JS carried out the experiments and data analysis and contributed to the draft of the manuscript. FS-R and SF supervised JS during DigiWest analysis that was performed at the NMI institute under the approval of MT. The data analysis was performed using tools provided by MT. CS and GG conceived the study, designed and coordinated the project. GG contributed to the writing of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the ALIVE Charity Foundation through the Research Innovation and Development Trust (RIDT), providing a scholarship to JS and bench fees. This work received financial support from the State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.

Acknowledgments

We would like to acknowledge the Institute of Molecular Medicine & Biobanking and the Faculty of Medicine & Surgery for the support in the use of the facilities at the University of Malta.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: International perspective. Int J Cancer (2013) 133:1–13. doi: 10.1002/ijc.27997
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 16:1647–55. doi:10.1093/emboj/16.7.1647
3. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U.S.A. (2006) 103:9773–8. doi:10.1073/pnas.0603948103
4. Wong LL, Chang CF, Kuo YS, Zhang D. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. Int J Oncol (2009) 34:1291–301. doi: 10.3892/ijo_00000256
5. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U.S.A. (2014) 111:9157–62. doi: 10.1073/pnas.1317630111
6. Risom T, Wang X, Liang J, Zhang X, Pelz C, Campbell LG, et al. Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. J Clin Invest (2020) 130:231–46. doi: 10.1172/JCI126390
Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells.

Cancers (Basel) (2017) 9:2371. doi: 10.3390/cancers90702371

9. Martinez V, V'Oeill S, Salmin J, Breslin S, Clayton A, Crown J, et al. Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncotarget (2017) 6:21635-216360. doi:10.18632/oncotarget.16363

23. Berns K, Hebebrand J, Fedini GC, Venturrelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol (2012) 227:658-67. doi: 10.1002/jcp.22773

50. Duhachek-Muggy S, Qi Y, Wise R, Alyahya L, Li H, Hodge J, et al. Protein kinase c-epsilon (PKCe) is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res (2002) 62:4132-41.

13. Nami B, Wang Z. HER2 in breast cancer stemness: A negative feedback loop towards trastuzumab resistance. Cancers (Basel) (2017) 9:40. doi: 10.3390/cancers9010040

29. Martinez VG, O’Keefe N, Salmin J, Breslin S, Clayton A, Crown J, et al. Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncotarget (2017) 6:21635-216360. doi:10.18632/oncotarget.16363

34. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollack M. Insulin-like growth factor-1 receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (2001) 93:1852-7. doi: 10.1093/jnci/93.24.1852

10. Scerri J, Baldacchino S, Sálica C, Scerri C, Grech G. Bead-based RNA multiplex panels for biomarker detection in oncology samples. Methods (2019) 158:86-91. doi: 10.1016/j.ymeth.2018.10.008

12. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of resistance to HER2-targeted therapy in human breast cancer. Cancer Cell (2007) 65:473-82. doi:10.1016/j.ccell.2007.08.030

26. Zazo S, González-Alonso P, Martin-Aparicio E, Chaminazo C, Cristóbal I, Arpi O, et al. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer (2016) 6:2661-78.

30. Martinez VG, O’Keefe N, Salmin J, Breslin S, Clayton A, Crown J, et al. Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles. Oncotarget (2017) 6:21635-216360. doi:10.18632/oncotarget.16363

60. Molina MA, Cordon-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res (2002) 62:4132-41.
52. Feldinger K, Generali D, Kramer-Marek G, Gijzen M, Ng TB, Wong JH, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget (2014) 5:6633–46. doi:10.18632/oncotarget.1955

53. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, et al. HER2-positive circulating tumor cells in breast cancer. PloS One (2011) 6:e15624. doi:10.1371/journal.pone.0015624

54. Cigna AT, Samec M, Koklesova I, Liskova A, Giordano FA, Kubatka P, et al. Cell-free nucleic acid patterns in disease prediction and monitoring - hype or hope? EPMA J (2020) 11:603–27. doi:10.1007/s13167-020-00226-x

55. Zhan X, Li J, Guo Y, Golubnitschaja O. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine. EPMA J (2021) 12:449–75. doi:10.1007/s13167-021-00265-y